ClinicalTrials.gg
CompletedNCT03751657Updated Apr 2, 2021Results posted

A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.

A Phase 2 interventional study of Insulin icodec and Placebo (insulin 287) in Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 49 sites in 7 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-04-02.

Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
247
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 27 studies testing insulin icodec in Diabetes Mellitus, Type 2 — 2 open to participants now, 2 under way, none of them phase 3. insulin icodec · Diabetes Mellitus, Type 2.

Enrollment
10th of 27
247 · median 84
Started
2018
with 1 other
Phase 2
3 of 27
none open now
Registered
5th of 27
by date
Lead sponsor
26 of 27
Novo Nordisk A/S

Among the 27 studies testing insulin icodec in Diabetes Mellitus, Type 2, this one is the 10th largest by enrollment, is one of 2 that started in 2018, is one of 3 in phase 2, and was the 5th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

2 of the 27 studies testing insulin icodec in Diabetes Mellitus, Type 2 are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About insulin icodec

insulin icodec: first FDA approval 2026 (AWIQLI FLEXTOUCH), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing insulin icodec in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The study compares 2 medicines for people with type 2 diabetes: insulin 287 (a new medicine) and insulin glargine (a medicine doctors can already prescribe). The study doctors will test insulin 287 to see how well it works compared to insulin glargine. The study will also test if insulin 287 is safe. The study participants will either get insulin 287 or insulin glargine (100 units/mL) - which treatment the participants get is decided by chance. The participants will need to inject their selves every day about the same time. Once a week the participant will need to take 1 extra injection on the same day of the week. The participants will have 16 clinic visits and 14 phone calls with the study doctor. During the study, the doctors will ask you to: 1) measure your blood sugar every day with a blood glucose meter using a finger prick, 2) write down different information in a paper diary daily and return this to your doctor, 3) wear a medical device to measure your blood sugar all the time for 2 weeks 5 times during the study.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, aged 18-75 years (both inclusive) at the time of signing
  • Diagnosed with type 2 diabetes mellitus greater than or equal to 180 days prior to the day of screening
  • of 7.0-9.5% (53-80 mmol/mol) (both inclusive) as assessed by central laboratory
  • Stable daily dose(s) for 90 days prior to the day of screening of any of the following antidiabetic drug(s) or combination regime(s): Any metformin formulations greater than or equal to 1500 mg or maximum tolerated or effective dose (as documented in subject's medical record) OR Any metformin formulations greater than or equal to 1500 mg or maximum tolerated or effective dose (as documented in subject medical record) with Dipeptidyl peptidase-4 inhibitor (DPP4i) (greater than or equal to half of the maximum approved dose according to local label or maximum tolerated or effective dose (as documented in subject's medical records)
  • Insulin naïve. However, short term insulin treatment for a maximum of 14 days prior to the day of screening is allowed, as is prior insulin treatment for gestational diabetes
  • (BMI) less than or equal to 40.0 kg/m\^2

Exclusion criteria

Exclusion Criteria:

  • Any episodes of diabetic ketoacidosis within the past 90 days prior to the day of screening and between screening and randomisation
  • Myocardial infarction, stroke, hospitalisation for unstable angina pectoris or within 180 days prior to the day of screening and between screening and randomisation
  • Presently classified as being in (NYHA) Class IV
  • Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within the past 90 days prior to the day of screening. However, short term insulin treatment for a maximum of 14 days prior to the day of screening is allowed, as is prior insulin treatment for gestational diabetes
  • Anticipated initiation or change in concomitant medications (for more than 14 consecutive days) known to affect weight or glucose metabolism (e.g. treatment with orlistat, thyroid hormones, or )
  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a pharmacologically pupil-dilated fundus examination performed by an ophthalmologist or another suitably qualified health care provider within the past 90 days prior to screening or in the period between screening and randomisation
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
247 participants (actual)

Study arms

  • Experimental
    Insulin 287

    Participants will receive once weekly insulin 287 and once daily placebo in combination with metformin with or without dipeptidyl peptidase-4 inhibitors (DPP4i) during 26 weeks of treatment period.

    Drug: Insulin icodec · Drug: Metformin · Drug: Dipeptidyl peptidase-4 inhibitors · Drug: Placebo (insulin glargine)

  • Active comparator
    Insulin glargine

    Participants will receive once daily insulin glargine and once weekly placebo in combination with metformin with or without DPP4i during 26 weeks of treatment period.

    Drug: Placebo (insulin 287) · Drug: Metformin · Drug: Dipeptidyl peptidase-4 inhibitors · Drug: Insulin glargine

Interventions

  • Insulin 287 once weekly subcutaneous (s.c.) injections at the starting dose of 70 units. Dose adjustment was done for the individual patient based on the three pre-breakfast self-measured plasma glucose values measured on two days prior to titration and on the day of the contact. The insulin dose adjustment should aim to reach an SMPG of 3.9-6.0 mmol/L (70-108 mg/dL)

    Also known as: Insulin 287

  • DrugPlacebo (insulin 287)

    Participants will receive once weekly s.c. injections of placebo equivalent to insulin 287.

  • Metformin is considered as non investigational medicinal product. Subject will continue metformin at stable pre-trial dose.

  • Dipeptidyl peptidase-4 inhibitors are considered as non investigational medicinal products. Subject will continue dipeptidyl peptidase-4 inhibitor at stable pre-trial dose.

  • Insulin glargine (100 U/mL) once daily s.c. injections at the starting dose of 10 units. Dose adjustment will be done for the individual patient based on the three pre-breakfast self-measured plasma glucose values measured on two days prior to titration and on the day of the contact. The insulin dose adjustment should aim to reach an SMPG of 3.9-6.0 mmol/L (70-108 mg/dL).

  • DrugPlacebo (insulin glargine)

    Participants will receive once daily s.c. injections of placebo equivalent to insulin glargine.

06

What researchers measure

Primary outcomes

  1. Change in Glycated Haemoglobin (HbA1c) [Percentage Point (%-Point)]

    Change in HbA1c from baseline (week 0) to week 26 is presented. The endpoint was evaluated based on the data from on-treatment without ancillary treatment period, starting at the date of first dose of trial product until the follow-up visit, or the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin, or initiation of any diabetes treatment other than trial products and metformin +/- DPP4i, or increase of the dose of metformin or DPP4i.

    Time frame: From baseline (Visit 2) to week 26 (Visit 28)

  2. Change in HbA1c [Millimoles/Mole (mmol/Mol)]

    Change in HbA1c from baseline (week 0) to week 26 is presented. The endpoint was evaluated based on the data from on-treatment without ancillary treatment period, starting at the date of first dose of trial product until the follow-up visit, or the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin, or initiation of any diabetes treatment other than trial products and metformin +/- DPP4i, or increase of the dose of metformin or DPP4i.

    Time frame: From baseline (Visit 2) to week 26 (Visit 28)

Secondary outcomes

  1. Change in Fasting Plasma Glucose

    Change in fasting plasma glucose from baseline (week 0) to week 26 is presented. The endpoint was evaluated based on the data from on-treatment without ancillary treatment period, starting at the date of first dose of trial product until the follow-up visit, or the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin, or initiation of any diabetes treatment other than trial products and metformin +/- DPP4i, or increase of the dose of metformin or DPP4i.

    Time frame: From baseline (Visit 2) to week 26 (Visit 28)

  2. 9-point Profile (Individual SMPG Values)

    Participants measured their plasma glucose (PG) levels using blood glucose meters (as plasma equivalent values of capillary whole blood glucose) at 9 time points (before breakfast, 90 minutes after the start of breakfast, before lunch, 90 minutes after the start of lunch, before dinner, 90 minutes after the start of dinner, at bedtime, at 4 am, before breakfast the following day). 9-point SMPG values after 26 weeks are presented. The endpoint was evaluated based on the data from on-treatment without ancillary treatment period, starting at the date of first dose of trial product until the follow-up visit, or the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin, or initiation of any diabetes treatment other than trial products and metformin +/- DPP4i, or increase of the dose of metformin or DPP4i.

    Time frame: Week 26 (Visit 28)

  3. Change in Mean of the 9-point Profile, Defined as the Area Under the Profile Divided by Measurement Time

    Participants measured their PG levels using blood glucose meters at 9 time points (before breakfast, 90 minutes after the start of breakfast, before lunch, 90 minutes after the start of lunch, before dinner, 90 minutes after the start of dinner, at bedtime, at 4 am, before breakfast the following day). The endpoint was evaluated based on the data from on-treatment without ancillary treatment period, starting at the date of first dose of trial product until the follow-up visit, or the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin, or initiation of any diabetes treatment other than trial products and metformin +/- DPP4i, or increase of the dose of metformin or DPP4i.

    Time frame: From baseline (Visit 2) to week 26 (Visit 28)

  4. Fluctuations of the 9-point Profile (Defined as the Integrated Absolute Distance From the Mean Profile Value Divided by Measurement Time).

    Participants measured their plasma glucose (PG) levels using blood glucose meters at 9 time points (before breakfast, 90 minutes after the start of breakfast, before lunch, 90 minutes after the start of lunch, before dinner, 90 minutes after the start of dinner, at bedtime, at 4 am, before breakfast the following day). Presented fluctuation in 9-point SMPG profile is the integrated absolute distance from the mean profile value divided by measurement time and is calculated using the trapezoidal method. The endpoint was evaluated based on the data from on-treatment without ancillary treatment period, starting at the date of first dose of trial product until the follow-up visit, or the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin, or initiation of any diabetes treatment other than trial products and metformin +/- DPP4i, or increase of the dose of metformin or DPP4i.

    Time frame: Week 26 (Visit 28)

  5. Fasting C-peptide

    Fasting C-peptide at week 26 is presented. The endpoint was evaluated based on the data from on-treatment without ancillary treatment period, starting at the date of first dose of trial product until the follow-up visit, or the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin, or initiation of any diabetes treatment other than trial products and metformin +/- DPP4i, or increase of the dose of metformin or DPP4i.

    Time frame: At week 26 (Visit 28)

  6. Change in Body Weight

    Change in body weight from baseline (week 0) to week 26 is presented. The endpoint was evaluated based on the data from on-treatment without ancillary treatment period, starting at the date of first dose of trial product until the follow-up visit, or the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin, or initiation of any diabetes treatment other than trial products and metformin +/- DPP4i, or increase of the dose of metformin or DPP4i.

    Time frame: From baseline (Visit 2) to week 26 (Visit 28)

  7. Weekly Dose of Insulin 287 and Weekly Dose of Insulin Glargine

    Weekly dose of insulin 287 and weekly dose of glargine at week 25 and week 26 are presented.The endpoint was evaluated based on the data from on-treatment without ancillary treatment period, starting at the date of first dose of trial product until the follow-up visit, or the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin, or initiation of any diabetes treatment other than trial products and metformin +/- DPP4i, or increase of the dose of metformin or DPP4i.

    Time frame: week 25 (Visit 27) and 26 (Visit 28)

  8. Number of Treatment Emergent Adverse Events (TEAEs)

    An adverse event (AE) is any untoward medical occurrence in a clinical trial subject administered or using a medicinal product, whether or not considered related to the medicinal product or usage. A TEAE was defined as an event that had onset date (or increase in severity) during the on-treatment observation period. The endpoint was evaluated based on the data from on-treatment period, starting at the date of first dose of trial product, and ending at follow-up visit, or the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin.

    Time frame: From baseline (Visit 2) to week 31 (Visit 30)

  9. Number of Hypoglycaemic Alert Episodes (Level 1) (≥3.0 and <3.9 mmol/L (≥54 and <70 mg/dL), Confirmed by BG Meter)

    Hypoglycaemia alert value (level 1) was defined as episodes that were sufficiently low for treatment with fast-acting carbohydrate and dose adjustment of glucose-lowering therapy with plasma glucose value of equal to or above (\>=) 3.0 and less than (\<) 3.9 mmol/L (\>= 54 and \< 70 mg/dL) confirmed by BG meter. Number of hypoglycaemic alert episodes (level 1) that occurred from week 0 to week 26 are presented.

    Time frame: From baseline (Visit 2) to week 26 (Visit 28)

  10. Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3)

    Clinically significant hypoglycaemic episodes (level 2) were defined as episodes that were sufficiently low to indicate serious, clinically important hypoglycaemia with plasma glucose value of less than (\<) 3.0 mmol/L (54 mg/dL). Severe hypoglycaemic episodes (level 3) were defined as episodes that were associated with severe cognitive impairment requiring external assistance for recovery. Number of clinically significant hypoglycaemic episodes (level 2), confirmed by blood glucose (BG) meter or severe hypoglycaemic episodes (level 3) that occurred from week 0 to week 26 are presented.

    Time frame: From baseline (Visit 2) to week 26 (Visit 28)

  11. Number of Severe Hypoglycaemic Episodes (Level 3)

    Severe hypoglycaemic episodes (level 3) were defined as episodes that were associated with severe cognitive impairment requiring external assistance for recovery. Number of severe hypoglycaemic episodes that occurred from week 0 to week 26 are presented.

    Time frame: From baseline (Visit 2) to week 26 (Visit 28)

  12. Change in Anti-insulin 287 Antibody Titres

    Samples from the insulin 287 arm of the study were analysed for anti-insulin 287 antibodies. Confirmed anti-insulin 287 antibody positive samples had an antibody titre value determined. The endpoint was evaluated based on the data from in-trial period, starting at randomisation, and ending at the last direct participant-site contact, or when participant withdrew their informed consent, or the last participant-investigator contact for participants lost to follow-up, or death.

    Time frame: From baseline (Visit 2) to week 31 (Visit 30)

  13. Change in Cross-reactive Anti-human Insulin Antibody Status (Positive/Negative)

    Anti-insulin 287 or glargine antibodies were classified as negative if % B/T was below a certain cut point. Samples positive for anti-insulin 287 or glargine antibodies were further tested for cross-reactivity to endogenous insulin. Samples not further tested are categorised as not applicable (NA). Unknown refers to samples with insufficient volume to perform analysis. The endpoint was evaluated based on the data from in-trial period, starting at randomisation, and ending at the last direct participant-site contact, or when participant withdrew their informed consent, or the last participant-investigator contact for participants lost to follow-up, or death.

    Time frame: From baseline (Visit 2) to week 31 (Visit 30)

  14. Change in Anti-insulin 287 Antibody Level

    Change in anti-insulin 287 antibodies level is not assessed because change in anti-insulin 287 antibody titres is a more meaningful way of describing the change in antibody levels. The results for change in anti-insulin 287 antibody titres are reported as a separate endpoint.

    Time frame: From baseline (Visit 2) to week 31 (Visit 30)

07

Results

Posted Feb 1, 2021

Participant flow

The trial was conducted at 49 sites in Canada (7), Czech Republic (9), Greece (5), Poland (6), Slovakia (6),Slovenia (2) and United States (14). One site in the United States screened, but didn't randomise any participant.

Participant flow — Overall Study
MilestoneInsulin 287Insulin Glargine
Started125122
Completed122119
Not completed33
Withdrew: Physician decision01
Withdrew: Withdrawal by subject11
Withdrew: Lost to follow-up21

Outcome measures

PrimaryChange in Glycated Haemoglobin (HbA1c) [Percentage Point (%-Point)]

Change in HbA1c from baseline (week 0) to week 26 is presented. The endpoint was evaluated based on the data from on-treatment without ancillary treatment period, starting at the date of first dose of trial product until the follow-up visit, or the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin, or initiation of any diabetes treatment other than trial products and metformin +/- DPP4i, or increase of the dose of metformin or DPP4i.

Time frame:
From baseline (Visit 2) to week 26 (Visit 28)
Reported as:
Least squares mean · Percentage point of HbA1c
Change in Glycated Haemoglobin (HbA1c) [Percentage Point (%-Point)]
Percentage point of HbA1cInsulin 287Insulin Glargine
Change in Glycated Haemoglobin (HbA1c) [Percentage Point (%-Point)]-1.33 ± 0.07-1.15 ± 0.07
Statistical analysis
  • Insulin 287 vs Insulin Glargine · Mixed Models Analysis · p = 0.0818 · Treatment difference: -0.18 · 95% CI -0.38 to 0.02
SecondaryChange in Fasting Plasma Glucose

Change in fasting plasma glucose from baseline (week 0) to week 26 is presented. The endpoint was evaluated based on the data from on-treatment without ancillary treatment period, starting at the date of first dose of trial product until the follow-up visit, or the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin, or initiation of any diabetes treatment other than trial products and metformin +/- DPP4i, or increase of the dose of metformin or DPP4i.

Time frame:
From baseline (Visit 2) to week 26 (Visit 28)
Reported as:
Least squares mean · mmol/l
Change in Fasting Plasma Glucose
mmol/lInsulin 287Insulin Glargine
Change in Fasting Plasma Glucose-3.20 ± 0.16-2.99 ± 0.16
Secondary9-point Profile (Individual SMPG Values)

Participants measured their plasma glucose (PG) levels using blood glucose meters (as plasma equivalent values of capillary whole blood glucose) at 9 time points (before breakfast, 90 minutes after the start of breakfast, before lunch, 90 minutes after the start of lunch, before dinner, 90 minutes after the start of dinner, at bedtime, at 4 am, before breakfast the following day). 9-point SMPG values after 26 weeks are presented. The endpoint was evaluated based on the data from on-treatment without ancillary treatment period, starting at the date of first dose of trial product until the follow-up visit, or the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin, or initiation of any diabetes treatment other than trial products and metformin +/- DPP4i, or increase of the dose of metformin or DPP4i.

Time frame:
Week 26 (Visit 28)
Reported as:
Least squares mean · mmol/l
9-point Profile (Individual SMPG Values)
mmol/lInsulin 287Insulin Glargine
Before breakfast5.70 ± 0.196.19 ± 0.19
90 minutes after start of breakfast7.90 ± 0.198.51 ± 0.19
Before lunch6.09 ± 0.196.19 ± 0.19
90 minutes after start of lunch7.83 ± 0.198.50 ± 0.19
Before main evening meal6.55 ± 0.196.96 ± 0.19
90 minutes after the start of main evening meal8.01 ± 0.198.47 ± 0.19
Before bedtime7.35 ± 0.197.87 ± 0.19
At 4:00 a.m.5.72 ± 0.195.98 ± 0.19
Before breakfast the following day5.74 ± 0.196.05 ± 0.19
SecondaryChange in Mean of the 9-point Profile, Defined as the Area Under the Profile Divided by Measurement Time

Participants measured their PG levels using blood glucose meters at 9 time points (before breakfast, 90 minutes after the start of breakfast, before lunch, 90 minutes after the start of lunch, before dinner, 90 minutes after the start of dinner, at bedtime, at 4 am, before breakfast the following day). The endpoint was evaluated based on the data from on-treatment without ancillary treatment period, starting at the date of first dose of trial product until the follow-up visit, or the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin, or initiation of any diabetes treatment other than trial products and metformin +/- DPP4i, or increase of the dose of metformin or DPP4i.

Time frame:
From baseline (Visit 2) to week 26 (Visit 28)
Reported as:
Least squares mean · mmol/l
Change in Mean of the 9-point Profile, Defined as the Area Under the Profile Divided by Measurement Time
mmol/lInsulin 287Insulin Glargine
Change in Mean of the 9-point Profile, Defined as the Area Under the Profile Divided by Measurement Time-2.70 ± 0.12-2.26 ± 0.12
SecondaryFluctuations of the 9-point Profile (Defined as the Integrated Absolute Distance From the Mean Profile Value Divided by Measurement Time).

Participants measured their plasma glucose (PG) levels using blood glucose meters at 9 time points (before breakfast, 90 minutes after the start of breakfast, before lunch, 90 minutes after the start of lunch, before dinner, 90 minutes after the start of dinner, at bedtime, at 4 am, before breakfast the following day). Presented fluctuation in 9-point SMPG profile is the integrated absolute distance from the mean profile value divided by measurement time and is calculated using the trapezoidal method. The endpoint was evaluated based on the data from on-treatment without ancillary treatment period, starting at the date of first dose of trial product until the follow-up visit, or the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin, or initiation of any diabetes treatment other than trial products and metformin +/- DPP4i, or increase of the dose of metformin or DPP4i.

Time frame:
Week 26 (Visit 28)
Reported as:
Least squares mean · mmol/l
Fluctuations of the 9-point Profile (Defined as the Integrated Absolute Distance From the Mean Profile Value Divided by Measurement Time).
mmol/lInsulin 287Insulin Glargine
Fluctuations of the 9-point Profile (Defined as the Integrated Absolute Distance From the Mean Profile Value Divided by Measurement Time).0.92 (0.84 to 1.01)0.94 (0.86 to 1.03)
SecondaryFasting C-peptide

Fasting C-peptide at week 26 is presented. The endpoint was evaluated based on the data from on-treatment without ancillary treatment period, starting at the date of first dose of trial product until the follow-up visit, or the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin, or initiation of any diabetes treatment other than trial products and metformin +/- DPP4i, or increase of the dose of metformin or DPP4i.

Time frame:
At week 26 (Visit 28)
Reported as:
Least squares mean · Nanomoles per liter (nmol/l)
Fasting C-peptide
Nanomoles per liter (nmol/l)Insulin 287Insulin Glargine
Fasting C-peptide0.44 (0.40 to 0.48)0.47 (0.43 to 0.51)
SecondaryChange in Body Weight

Change in body weight from baseline (week 0) to week 26 is presented. The endpoint was evaluated based on the data from on-treatment without ancillary treatment period, starting at the date of first dose of trial product until the follow-up visit, or the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin, or initiation of any diabetes treatment other than trial products and metformin +/- DPP4i, or increase of the dose of metformin or DPP4i.

Time frame:
From baseline (Visit 2) to week 26 (Visit 28)
Reported as:
Least squares mean · Kilogram
Change in Body Weight
KilogramInsulin 287Insulin Glargine
Change in Body Weight1.49 ± 0.361.56 ± 0.37
SecondaryWeekly Dose of Insulin 287 and Weekly Dose of Insulin Glargine

Weekly dose of insulin 287 and weekly dose of glargine at week 25 and week 26 are presented.The endpoint was evaluated based on the data from on-treatment without ancillary treatment period, starting at the date of first dose of trial product until the follow-up visit, or the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin, or initiation of any diabetes treatment other than trial products and metformin +/- DPP4i, or increase of the dose of metformin or DPP4i.

Time frame:
week 25 (Visit 27) and 26 (Visit 28)
Reported as:
Least squares mean · Units of Insulin
Weekly Dose of Insulin 287 and Weekly Dose of Insulin Glargine
Units of InsulinInsulin 287Insulin Glargine
Weekly Dose of Insulin 287 and Weekly Dose of Insulin Glargine229.06 (205.08 to 255.83)284.05 (253.97 to 317.71)
SecondaryNumber of Treatment Emergent Adverse Events (TEAEs)

An adverse event (AE) is any untoward medical occurrence in a clinical trial subject administered or using a medicinal product, whether or not considered related to the medicinal product or usage. A TEAE was defined as an event that had onset date (or increase in severity) during the on-treatment observation period. The endpoint was evaluated based on the data from on-treatment period, starting at the date of first dose of trial product, and ending at follow-up visit, or the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin.

Time frame:
From baseline (Visit 2) to week 31 (Visit 30)
Reported as:
Number · Events
Number of Treatment Emergent Adverse Events (TEAEs)
EventsInsulin 287Insulin Glargine
Number of Treatment Emergent Adverse Events (TEAEs)229158
SecondaryNumber of Hypoglycaemic Alert Episodes (Level 1) (≥3.0 and <3.9 mmol/L (≥54 and <70 mg/dL), Confirmed by BG Meter)

Hypoglycaemia alert value (level 1) was defined as episodes that were sufficiently low for treatment with fast-acting carbohydrate and dose adjustment of glucose-lowering therapy with plasma glucose value of equal to or above (\>=) 3.0 and less than (\<) 3.9 mmol/L (\>= 54 and \< 70 mg/dL) confirmed by BG meter. Number of hypoglycaemic alert episodes (level 1) that occurred from week 0 to week 26 are presented.

Time frame:
From baseline (Visit 2) to week 26 (Visit 28)
Reported as:
Number · Episodes
Number of Hypoglycaemic Alert Episodes (Level 1) (≥3.0 and <3.9 mmol/L (≥54 and <70 mg/dL), Confirmed by BG Meter)
EpisodesInsulin 287Insulin Glargine
Number of Hypoglycaemic Alert Episodes (Level 1) (≥3.0 and <3.9 mmol/L (≥54 and <70 mg/dL), Confirmed by BG Meter)358145
SecondaryNumber of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3)

Clinically significant hypoglycaemic episodes (level 2) were defined as episodes that were sufficiently low to indicate serious, clinically important hypoglycaemia with plasma glucose value of less than (\<) 3.0 mmol/L (54 mg/dL). Severe hypoglycaemic episodes (level 3) were defined as episodes that were associated with severe cognitive impairment requiring external assistance for recovery. Number of clinically significant hypoglycaemic episodes (level 2), confirmed by blood glucose (BG) meter or severe hypoglycaemic episodes (level 3) that occurred from week 0 to week 26 are presented.

Time frame:
From baseline (Visit 2) to week 26 (Visit 28)
Reported as:
Number · Episodes
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3)
EpisodesInsulin 287Insulin Glargine
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3)3831
SecondaryNumber of Severe Hypoglycaemic Episodes (Level 3)

Severe hypoglycaemic episodes (level 3) were defined as episodes that were associated with severe cognitive impairment requiring external assistance for recovery. Number of severe hypoglycaemic episodes that occurred from week 0 to week 26 are presented.

Time frame:
From baseline (Visit 2) to week 26 (Visit 28)
Reported as:
Number · Episodes
Number of Severe Hypoglycaemic Episodes (Level 3)
EpisodesInsulin 287Insulin Glargine
Number of Severe Hypoglycaemic Episodes (Level 3)10
SecondaryChange in Anti-insulin 287 Antibody Titres

Samples from the insulin 287 arm of the study were analysed for anti-insulin 287 antibodies. Confirmed anti-insulin 287 antibody positive samples had an antibody titre value determined. The endpoint was evaluated based on the data from in-trial period, starting at randomisation, and ending at the last direct participant-site contact, or when participant withdrew their informed consent, or the last participant-investigator contact for participants lost to follow-up, or death.

Time frame:
From baseline (Visit 2) to week 31 (Visit 30)
Reported as:
Mean · Antibody titers
Change in Anti-insulin 287 Antibody Titres
Antibody titersInsulin 287
Change in Anti-insulin 287 Antibody Titres979.9 ± 3177.9
SecondaryChange in Cross-reactive Anti-human Insulin Antibody Status (Positive/Negative)

Anti-insulin 287 or glargine antibodies were classified as negative if % B/T was below a certain cut point. Samples positive for anti-insulin 287 or glargine antibodies were further tested for cross-reactivity to endogenous insulin. Samples not further tested are categorised as not applicable (NA). Unknown refers to samples with insufficient volume to perform analysis. The endpoint was evaluated based on the data from in-trial period, starting at randomisation, and ending at the last direct participant-site contact, or when participant withdrew their informed consent, or the last participant-investigator contact for participants lost to follow-up, or death.

Time frame:
From baseline (Visit 2) to week 31 (Visit 30)
Reported as:
Count of participants · Participants
Change in Cross-reactive Anti-human Insulin Antibody Status (Positive/Negative)
ParticipantsInsulin 287Insulin Glargine
Week 0 — Negative01
Week 0 — Positive00
Week 0 — Unknown19
Week 0 — Not Applicable124112
Week 31 — Negative90
Week 31 — Positive8626
Week 31 — Unknown00
Week 31 — Not Applicable2589
PrimaryChange in HbA1c [Millimoles/Mole (mmol/Mol)]

Change in HbA1c from baseline (week 0) to week 26 is presented. The endpoint was evaluated based on the data from on-treatment without ancillary treatment period, starting at the date of first dose of trial product until the follow-up visit, or the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin, or initiation of any diabetes treatment other than trial products and metformin +/- DPP4i, or increase of the dose of metformin or DPP4i.

Time frame:
From baseline (Visit 2) to week 26 (Visit 28)
Reported as:
Least squares mean · mmol/mol
Change in HbA1c [Millimoles/Mole (mmol/Mol)]
mmol/molInsulin 287Insulin Glargine
Change in HbA1c [Millimoles/Mole (mmol/Mol)]-14.51 ± 0.79-12.54 ± 0.80
Statistical analysis
  • Insulin 287 vs Insulin Glargine · Mixed Models Analysis · p = 0.0818 · Treatment difference: -1.97 · 95% CI -4.19 to 0.25
SecondaryChange in Anti-insulin 287 Antibody Level

Change in anti-insulin 287 antibodies level is not assessed because change in anti-insulin 287 antibody titres is a more meaningful way of describing the change in antibody levels. The results for change in anti-insulin 287 antibody titres are reported as a separate endpoint.

Time frame:
From baseline (Visit 2) to week 31 (Visit 30)

No measurements were reported for this outcome.

Adverse events

Collected over Week 0 to Week 31 Results are based on the SAS which included all participants who received at least one dose of Insulin 287 or Insulin glargine. The SAS included all participants who received at least one dose of the investigational product or comparator.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Insulin 2870/125 (0%)2/125 (1.6%)26/125 (20.8%)
Insulin Glargine0/122 (0%)3/122 (2.5%)16/122 (13.1%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventInsulin 287Insulin Glargine
Acute kidney injuryRenal and urinary disorders0/1251/122
AnaemiaBlood and lymphatic system disorders0/1251/122
AzotaemiaRenal and urinary disorders0/1251/122
Cerebral disorderNervous system disorders0/1251/122
Coronary artery diseaseCardiac disorders0/1251/122
Emphysematous pyelonephritisInfections and infestations0/1251/122
HepatosplenomegalyHepatobiliary disorders0/1251/122
HydronephrosisRenal and urinary disorders0/1251/122
HypomagnesaemiaMetabolism and nutrition disorders0/1251/122
LeukocytosisBlood and lymphatic system disorders0/1251/122
Most frequent other events
Most frequent other events
EventInsulin 287Insulin Glargine
HeadacheNervous system disorders14/1253/122
NasopharyngitisInfections and infestations10/1258/122
Upper respiratory tract infectionInfections and infestations7/1256/122

Baseline characteristics

Full analysis set (FAS) included all randomised participants.

Age, Continuous
Age, Continuous(Years)Insulin 287Insulin GlargineTotal
Mean59.7 ± 8.259.4 ± 9.559.6 ± 8.9
Sex: Female, Male
Sex: Female, Male(Participants)Insulin 287Insulin GlargineTotal
Female5553108
Male7069139
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Insulin 287Insulin GlargineTotal
Hispanic or Latino10616
Not Hispanic or Latino115116231
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Insulin 287Insulin GlargineTotal
American Indian or Alaska Native000
Asian8412
Native Hawaiian or Other Pacific Islander101
Black or African American7512
White109113222
More than one race000
Unknown or Not Reported000
08

Study locations

49 sites
  • Novo Nordisk Investigational Site
    Lancaster, California 93534, United States
  • Novo Nordisk Investigational Site
    Ventura, California 93003, United States
  • Novo Nordisk Investigational Site
    Walnut Creek, California 94598, United States
  • Novo Nordisk Investigational Site
    Roswell, Georgia 30076, United States
  • Novo Nordisk Investigational Site
    Lexington, Kentucky 40503, United States
  • Novo Nordisk Investigational Site
    Las Vegas, Nevada 89128, United States
  • Novo Nordisk Investigational Site
    Charlotte, North Carolina 28277, United States
  • Novo Nordisk Investigational Site
    Whiteville, North Carolina 28472, United States
  • Novo Nordisk Investigational Site
    Chattanooga, Tennessee 37404, United States
  • Novo Nordisk Investigational Site
    Chattanooga, Tennessee 37411, United States
  • Novo Nordisk Investigational Site
    Austin, Texas 78731, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75230, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75390-9302, United States
  • Novo Nordisk Investigational Site
    Renton, Washington 98057, United States
  • Novo Nordisk Investigational Site
    Halifax, Nova Scotia B3H 1V7, Canada
  • Novo Nordisk Investigational Site
    Brampton, Ontario L6S 0C6, Canada
  • Novo Nordisk Investigational Site
    Concord, Ontario L4K 4M2, Canada
  • Novo Nordisk Investigational Site
    Etobicoke, Ontario M9R 4E1, Canada
  • Novo Nordisk Investigational Site
    Hamilton, Ontario L8M 1K7, Canada
  • Novo Nordisk Investigational Site
    Sarnia, Ontario N7T 4X3, Canada
  • Novo Nordisk Investigational Site
    St-Marc-des-Carrières, Quebec G0A 4B0, Canada
  • Novo Nordisk Investigational Site
    Brno, 62500, Czechia
  • Novo Nordisk Investigational Site
    Pardubice, 530 02, Czechia
  • Novo Nordisk Investigational Site
    Praha 1, 110 00, Czechia
  • Novo Nordisk Investigational Site
    Praha 4, 149 00, Czechia
  • Novo Nordisk Investigational Site
    Praha 5, 150 00, Czechia
  • Novo Nordisk Investigational Site
    Praha 8, 181 00, Czechia
  • Novo Nordisk Investigational Site
    Praha, 128 08, Czechia
  • Novo Nordisk Investigational Site
    Rakovník, 269 01, Czechia
  • Novo Nordisk Investigational Site
    Slaný, 27401, Czechia
  • Novo Nordisk Investigational Site
    Athens, 115 25, Greece
  • Novo Nordisk Investigational Site
    Athens, GR-11527, Greece
  • Novo Nordisk Investigational Site
    Thessaloniki, GR-54636, Greece
  • Novo Nordisk Investigational Site
    Thessaloniki, GR-54642, Greece
  • Novo Nordisk Investigational Site
    Thessaloniki, GR-57010, Greece
  • Novo Nordisk Investigational Site
    Bialystok, 15-404, Poland
  • Novo Nordisk Investigational Site
    Gdansk, 80-546, Poland
  • Novo Nordisk Investigational Site
    Lodz, 90-132, Poland
  • Novo Nordisk Investigational Site
    Poznan, 61-251, Poland
  • Novo Nordisk Investigational Site
    Warsaw, 00-465, Poland
  • Novo Nordisk Investigational Site
    Wierzchoslawice, 33-122, Poland
  • Novo Nordisk Investigational Site
    Bratislava, 821 02, Slovakia
  • Novo Nordisk Investigational Site
    Bratislava, 851 01, Slovakia
  • Novo Nordisk Investigational Site
    Kosice, 040 01, Slovakia
  • Novo Nordisk Investigational Site
    Moldava nad Bodvou, 045 01, Slovakia
  • Novo Nordisk Investigational Site
    Sahy, 93601, Slovakia
  • Novo Nordisk Investigational Site
    Trencin, 91101, Slovakia
  • Novo Nordisk Investigational Site
    Koper, SI-6000, Slovenia
  • Novo Nordisk Investigational Site
    Ljubljana, SI-1000, Slovenia
09

References and documents

Publications

  • Rosenstock J, Bajaj HS, Janež A, Silver R, Begtrup K, Hansen MV, Jia T, Goldenberg R. Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment. PMID:32960514
  • Rosenstock J, Bajaj HS, Janez A, Silver R, Begtrup K, Hansen MV, Jia T, Goldenberg R; NN1436-4383 Investigators. Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment. N Engl J Med. 2020 Nov 26;383(22):2107-2116. doi: 10.1056/NEJMoa2022474. Epub 2020 Sep 22. PubMed 32960514 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Dec 2019, 12 months.

Results were first posted in Feb 2021, 1 year 1 month after primary completion.

Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 12 months is close to that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2018
First posted
Nov 23, 2018
StartActual
Nov 29, 2018
Primary completionActual
Dec 16, 2019
CompletionActual
Jan 17, 2020
Results first posted
Feb 1, 2021
Last update
Apr 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03751657
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Nov 23, 2018
Start date
Nov 29, 2018
Primary completion
Dec 16, 2019
Completion
Jan 17, 2020
Results posted
Feb 1, 2021
Last update
Apr 2, 2021

Study contacts

Clinical Reporting Anchor and Disclosure (1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin icodec

Start the discussion